|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Antonia SJ, López-Martin JA, Bendell J,
Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F,
et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent
small-cell lung cancer (CheckMate 032): A multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 17:883–895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh N, Temin S, Baker S Jr, Blanchard E,
Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, et
al: Therapy for Stage IV Non-Small-Cell lung cancer with driver
alterations: ASCO living guideline. J Clin Oncol. 40:3310–3322.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones GS and Baldwin DR: Recent advances
in the management of lung cancer. Clin Med (Lond). 18 (Suppl
2):S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in Non-Small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Janning M, Kobus F, Babayan A, Wikman H,
Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Bottcher LM,
et al: Determination of PD-L1 expression in circulating tumor cells
of NSCLC patients and correlation with response to PD-1/PD-L1
inhibitors. Cancers (Basel). 11:8352019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen YL, Huang WC, Lin FM, Hsieh HB, Hsieh
CH, Hsieh RK, Chen KW, Yen MH, Lee J, Su S, et al: Novel
circulating tumor cell-based blood test for the assessment of PD-L1
protein expression in treatment-naive, newly diagnosed patients
with non-small cell lung cancer. Cancer Immunol Immunother.
68:1087–1094. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N,
Li D, Wang R, Dang Y, Hu Z, et al: Dynamic change of PD-L1
expression on circulating tumor cells in advanced solid tumor
patients undergoing PD-1 blockade therapy. Oncoimmunology.
7:e14381112018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang J, Dallmann R, Lu R, Yan J and
Charmet J: Flow Rate-Independent multiscale liquid biopsy for
precision oncology. ACS Sens. 8:1200–1210. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mei ZF, Yan J, Qian L, He YC, Feng JJ,
Wang J, Jie ZJ and Zou H: Enrichment of circulating tumor cells of
lung cancer and correlation with serum leukomonocyte and tumor
biomarkers: A retrospective study. Technol Cancer Res Treat.
22:20710575812023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahn MJ, Mendoza MJL, Pavlakis N, Kato T,
Soo RA, Kim DW, Liam CK, Hsia TC, Lee CK, Reungwetwattana T, et al:
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus
Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic
Considerations. Clin Lung Cancer. 23:670–685. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esposito G, Palumbo G, Carillio G, Manzo
A, Montanino A, Sforza V, Costanzo R, Sandomenico C, La Manna C,
Martucci N, et al: Immunotherapy in small cell lung cancer. Cancers
(Basel). 12:25222020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong D, Zhang W, Yang Z, Li G, Cheng S,
Zhang K and Feng L: Correlation between PD-L1 expression ON CTCs
and prognosis of patients with cancer: A systematic review and
meta-analysis. Oncoimmunology. 10:19384762021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guibert N, Delaunay M, Lusque A, Boubekeur
N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre
G, et al: PD-L1 expression in circulating tumor cells of advanced
non-small cell lung cancer patients treated with nivolumab. Lung
Cancer. 120:108–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dill EA, Gru AA, Atkins KA, Friedman LA,
Moore ME, Bullock TN, Cross JV, Dillon PM and Mills AM: PD-L1
Expression and intratumoral heterogeneity across breast cancer
subtypes and stages: An assessment of 245 primary and 40 metastatic
tumors. Am J Surg Pathol. 41:334–342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li
K, Nishiyama A, Arai S, Yano S and Wang W: EGFR-TKI resistance
promotes immune escape in lung cancer via increased PD-L1
expression. Mol Cancer. 18:1652019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma LX, Wang Y, Espin-Garcia O, Allen MJ,
Jang GH, Zhang A, Dodd A, Ramotar S, Hutchinson S, Tehfe M, et al:
Systemic inflammatory prognostic scores in advanced pancreatic
adenocarcinoma. Br J Cancer. 128:1916–1921. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaitsu J, Yamashita Y, Ishikawa A, Saito
A, Kagimoto A, Mimura T, Hirakawa T, Mito M, Fukuhara K, Senoo T,
et al: Systemic inflammatory score predicts response and prognosis
in patients with lung cancer treated with immunotherapy. Anticancer
Res. 41:3673–3682. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Wang Y, Zhang X and Zhang T:
Pretreatment prognostic nutritional index as a prognostic factor in
lung cancer: Review and meta-analysis. Clin Chim Acta. 486:303–310.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bahceci A, Kotek SA and Isik D: The
prognostic values of prognostic nutritional index in
extensive-stage small-cell lung cancer. Anticancer Drugs.
33:e534–e540. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ayoub M, Eleneen Y and Colen RR: Cancer
Imaging in Immunotherapy. Adv Exp Med Biol. 1244:309–324. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Magbanua M, Savenkov O, Asmus EJ, Ballman
KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP
and Rugo HS: Clinical significance of circulating tumor cells in
hormone receptor-positive metastatic breast cancer patients who
received letrozole with or without bevacizumab. Clin Cancer Res.
26:4911–4920. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graf RP, Hullings M, Barnett ES, Carbone
E, Dittamore R and Scher HI: Clinical Utility of the
Nuclear-localized AR-V7 biomarker in circulating tumor cells in
improving physician treatment choice in castration-resistant
prostate cancer. Eur Urol. 77:170–177. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma K, Qiao Y, Wang H and Wang S:
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung
adenocarcinoma. Ann Transl Med. 8:14782020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niu D, Chen Y, Mi H, Mo Z and Pang G: The
epiphany derived from T-cell-inflamed profiles: Pan-cancer
characterization of CD8A as a biomarker spanning clinical
relevance, cancer prognosis, immunosuppressive environment, and
treatment responses. Front Genet. 13:9744162022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim
TM, Jeon YK, Kim DW, Chung DH and Heo DS: Pan-Cancer immunogenomic
perspective on the tumor microenvironment based on PD-L1 and CD8
T-Cell infiltration. Clin Cancer Res. 22:2261–2270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang SL, Yu GY, Yao J, Li ZS, Mao AR and
Bai Y: Diagnostic role of carbohydrate antigen 72-4 for
gastrointestinal malignancy screening in Chinese patients: A
prospective study. J Dig Dis. 19:685–692. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y, Zhang P, Zhang K and Huang C: The
application of CA72-4 in the diagnosis, prognosis, and treatment of
gastric cancer. Biochim Biophys Acta Rev Cancer. 187:1886342021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su Y, Lu C, Zheng S, Zou H, Shen L, Yu J,
Weng Q, Wang Z, Chen M, Zhang R, et al: Precise prediction of the
sensitivity of platinum chemotherapy in SCLC: Establishing and
verifying the feasibility of a CT-based radiomics nomogram. Front
Oncol. 13:10061722023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guijarro LG, Justo BF, Boaru DL, De
Castro-Martinez P, De Leon-Oliva D, Fraile-Martinez O,
Garcia-Montero C, Alvarez-Mon M, Toledo-Lobo M and Ortega MA: Is
Insulin Receptor Substrate4 (IRS4) a platform involved in the
activation of several oncogenes? Cancers (Basel). 15:46512023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Leon-Oliva D, Barrena-Blazquez S,
Jimenez-Alvarez L, Fraile-Martinez O, Garcia-Montero C,
Lopez-Gonzalez L, Torres-Carranza D, Garcia-Puente LM, Carranza ST,
Alvarez-Mon MA, et al: The RANK-RANKL-OPG System: A multifaceted
regulator of homeostasis, immunity, and cancer. Medicina (Kaunas).
59:17522023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cristescu R, Mogg R, Ayers M, Albright A,
Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al:
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based
immunotherapy. Science. 362:eaar35932018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Auslander N, Zhang G, Lee JS, Frederick
DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, et al:
Robust prediction of response to immune checkpoint blockade therapy
in metastatic melanoma. Nat Med. 24:1545–1549. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roy S and Trinchieri G: Microbiota: A key
orchestrator of cancer therapy. Nat Rev Cancer. 17:271–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
